The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.

about

The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.

Item

http://www.wikidata.org/entity/Q39003028

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@en

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@nl

type

Item

label

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@en

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@nl

prefLabel

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@en

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@nl

P1476

The magnitude of neurotoxicity ...... ation-based PROFILES registry.

@en

P2093

Antoinetta J M Beijers

http://www.w3.org/2001/XMLSchema#string

Art Vreugdenhil

http://www.w3.org/2001/XMLSchema#string

Floortje Mols

http://www.w3.org/2001/XMLSchema#string

Lonneke V van de Poll-Franse

http://www.w3.org/2001/XMLSchema#string

Marijke Eurelings

http://www.w3.org/2001/XMLSchema#string

Monique C Minnema

http://www.w3.org/2001/XMLSchema#string

Simone Oerlemans

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy-induced peripheral neurotoxicity: a critical analysis

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Improved survival in multiple myeloma and the impact of novel therapies.

P304

653-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-2927-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28116479

http://www.w3.org/2001/XMLSchema#string

P921

neurotoxicity